Monitor for subsequent development milestones from Velocity Bioworks regarding closed-system and continuous monitoring capabilities. No near-term revenue catalyst is expected from this early-stage proof-of-concept.
Price Chart
Executive Summary
Valion Bio announced that its wholly owned CDMO subsidiary, Velocity Bioworks, completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform, demonstrating a correlation between NMR signals and microbial cell density during fermentation. This is an early-stage proof-of-concept milestone for a non-invasive, real-time bioprocess monitoring technology, but no financial terms, revenue impact, or definitive commercialization timeline were disclosed.
Key Facts
- Velocity Bioworks completed initial feasibility evaluation of LarmorBio's BioScan-NMR platform less than six months after Valion secured exclusive rights.
- The evaluation showed a strong correlation between NMR signal and optical density (OD600), a proxy for cell density in microbial fermentation.
- The technology is being developed for continuous, real-time, non-invasive monitoring of cell size, density, viability, and phenotype within bioreactors.
- No financial terms, development costs, or revenue projections were disclosed in the filing.
- The project remains an early-stage proof-of-concept; subsequent development activities are planned but not yet initiated.
Financial Impact
No financial figures disclosed; the filing describes an early-stage technology evaluation with no revenue or cost impact reported.
Risk Factors
- The technology is at an early proof-of-concept stage and may not successfully scale or achieve commercial deployment.
- No financial terms or development budget were disclosed, making it impossible to assess the capital commitment or ROI.
- Valion Bio's primary pipeline (Entolimod, Entolasta) remains pre-commercial and capital-intensive; this CDMO initiative does not alter the company's cash runway or regulatory risk profile.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007857 |
| Document: valion_ex9901.htm | 0001683168-26-007857 |
| Document: 0001683168-26-007857-index-headers.html | 0001683168-26-007857 |
| Document: 0001683168-26-007857-index.html | 0001683168-26-007857 |
| Document: 0001683168-26-007857.txt | 0001683168-26-007857 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.7820 (+12.63%) |
Oct 26, 2026 1d ago | 8-K | $0.8400 | awaiting T+20 | — | $0.7820 (−6.90%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.7820 (−18.20%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 16, 2026 11d ago | S-3 | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 16, 2026 11d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.7820 (−36.42%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.7820 (−46.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.7820 (+64.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers